Market Overview

Shire CEO: Baxalta Deal 'Creates Significant Value' And Will Create The World's Leading Rare Disease Company 'By A Wide Margin'


Shire PLC (ADR) (NASDAQ: SHPG)'s CEO, Flemming Ornskov was a guest on CNBC's "Closing Bell" on Tuesday to discuss the company's acquisition of Baxalta Inc (NYSE: BXLT).

Ornskov said Shire's $32 billion acquisition of Baxalta is a "very good deal" and the company's long-term investors "totally understand it." He added that the acquisition "creates significant value for shareholders" in addition to creating a "unique platform that is going to be the world's leading rare disease company by a wide margin."

Related Link: Shire-Baxalta Combination Official, Shareholders Get $18 In Cash And Rest In Shares

Ornskov also noted that the rare disease segment is "one of the most attractive" segments of healthcare as there are more than 7,000 rare diseases, many of which have no treatment. As such, a joint Shire-Baxalta entity will represent a "patient focused culture."

Finally, Ornskov argued that Shire's acquisition of Baxalta is "not about [tax] inversion" as it is "about growth and creating a leader in rare diseases."

Posted-In: Baxalta CNBC Flemming Ornskov Shire Shire Baxalta MergerM&A News Media


Related Articles (SHPG + BXLT)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at